Department of Operating Theatres and Evidence Based Surgery, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands.
Br J Surg. 2014 Jan;101(1):e65-79. doi: 10.1002/bjs.9346. Epub 2013 Nov 22.
Some 15 per cent of all patients with acute pancreatitis develop necrotizing pancreatitis, with potentially significant consequences for both patients and healthcare services.
This review summarizes the latest insights into the surgical and medical management of necrotizing pancreatitis. General management strategies for the treatment of complications are discussed in relation to the stage of the disease.
Frequent clinical evaluation of the patient's condition remains paramount in the first 24-72 h of the disease. Liberal goal-directed fluid resuscitation and early enteral nutrition should be provided. Urgent endoscopic retrograde cholangiopancreatography is indicated when cholangitis is suspected, but it is unclear whether this is appropriate in patients with predicted severe biliary pancreatitis without cholangitis. Antibiotic prophylaxis does not prevent infection of necrosis and antibiotics are not indicated as part of initial management. Bacteriologically confirmed infections should receive targeted antibiotics. With the more conservative approach to necrotizing pancreatitis currently advocated, fine-needle aspiration culture of pancreatic or extrapancreatic necrosis will less often lead to a change in management and is therefore indicated less frequently. Optimal treatment of infected necrotizing pancreatitis consists of a staged multidisciplinary 'step-up' approach. The initial step is drainage, either percutaneous or transluminal, followed by surgical or endoscopic transluminal debridement only if needed. Debridement is delayed until the acute necrotic collection has become 'walled-off'.
Outcome following necrotizing pancreatitis has improved substantially in recent years as a result of a shift from early surgical debridement to a staged, minimally invasive, multidisciplinary, step-up approach.
约 15%的急性胰腺炎患者会发展为坏死性胰腺炎,这对患者和医疗服务都有潜在的重大影响。
本综述总结了坏死性胰腺炎的最新外科和内科治疗进展。本文将讨论与疾病分期相关的并发症治疗的一般管理策略。
在疾病的最初 24-72 小时内,频繁的临床评估仍然是最重要的。应进行充分的目标导向液体复苏和早期肠内营养。当怀疑胆管炎时,应进行紧急内镜逆行胰胆管造影,但对于无胆管炎的预测性重症胆源性胰腺炎患者,是否适合行该检查仍不清楚。抗生素预防并不能预防坏死感染,抗生素也不应作为初始治疗的一部分。对于确诊的感染性坏死,应使用针对性抗生素。目前提倡更为保守的坏死性胰腺炎处理方法,细针抽吸胰腺或胰外坏死组织培养将较少改变治疗方法,因此指征也较少。感染性坏死性胰腺炎的最佳治疗方法是分阶段的多学科“逐步升级”方法。初始步骤是引流,经皮或经腔内,仅在需要时才进行外科或内镜腔内清创。清创应延迟到急性坏死性积聚形成“包裹性”。
近年来,由于从早期外科清创术转变为分阶段、微创、多学科、逐步升级的方法,坏死性胰腺炎的预后得到了显著改善。